Cancer News and Research

Latest Cancer News and Research

FDA accepts ProStrakan's Abstral NDA filing for review

Orexo AB (STO:ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK), has announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Elekta Impac Software to demonstrate its integrated oncology EHR, MOSAIQ at EHR Symposium

Elekta Impac Software has been selected to demonstrate at the 2009 American Society of Clinical Oncology (ASCO) Electronic Health Records (EHR) Symposium: Harnessing the EHR, From Incentives to Sustainability, October 6-7, in San Francisco, California.

From Elekta 6 Oct 2009

New institutional advertising campaign based on real stories

NYU Langone Medical Center will launch a new institutional advertising campaign based on real stories from the Medical Center beginning on October 5, 2009. The campaign, “Any Given Moment,” captures and conveys some of the most powerful, intimate and uniquely human experiences to emerge from the Medical Center and features the Medical Center’s core clinical care and research strengths.

6 Oct 2009

Key defence mechanism used by the immune system against Listeria identified

A team of University of British Columbia microbiologists has identified a key defence mechanism used by the immune system against Listeria with strong implications for the future development of vaccines.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

Researchers at The Wistar Institute have identified a key gene (KLF17) involved in the spread of breast cancer throughout the body. They also demonstrated that expression of KLF17 together with another gene (Id1) known to regulate breast cancer metastasis accurately predicts whether the disease will spread to the lymph nodes.

6 Oct 2009

New method to predict risk of breast cancer

Mayo Clinic researchers have found that certain structural features within breast tissue can indicate a woman's individual cancer risk. The findings appear online today in the Journal of Clinical Oncology.

6 Oct 2009

Summa Health System to implement ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Summa Health System has selected ProVation® MD software for Cardiology procedure documentation and coding.

6 Oct 2009

Two-thirds of tonsil tumour samples show evidence of HPV-16 gene: Study

It is estimated that more than 7,000 people are diagnosed with head and neck cancer each year in the UK and approximately 3,500 cases result in death. These cancers include tumours of the mouth, lips, throat and voice-box, and some have been linked to the sexually transmitted infection, HPV-16. Scientists at Liverpool analysed the DNA of more than 90 cancerous tissue samples to look for genes that indicated infection.

6 Oct 2009

BioImagene announces launch of the Virtuoso digital pathology solution

BioImagene, the leading provider of innovative digital pathology solutions, today announced the availability of the next generation of its digital pathology solution, VirtuosoTM. A highlight in this version is the ability to share cases in real time, allowing pathologists to collaborate with each other to sign out cases. Virtuoso users can participate in peer reviews, perform second-opinions for difficult cases, and guide residents in the review of cases for education.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Winner of 2009 NAMS award

Michael Holick, PhD, MD, director of the Bone Healthcare Clinic and the Vitamin D, Skin and Bone Research Laboratory at Boston University School of Medicine BUSM recently received the 2009 NAMS/Upsher-Smith Laboratories, Inc.Vitamin D Research Award from the North American Menopause Society (NAMS).

6 Oct 2009

Absence of certain proteins for proper cell duplication can lead to cancer

A Purdue University researcher has discovered that the absence of certain proteins needed for proper cell duplication can lead to cancer.

6 Oct 2009

Alcohol-impaired drivers account for higher emergency department costs

The costs of drinking and driving are all too apparent, with alcohol involved in 41 percent of all motor vehicle crash fatalities in 2006. In addition to the mortality and morbidity associated with drinking and driving, the economic impact of alcohol impaired driving is considerable, estimated at $51 billion, with medical costs accounting for 15 percent of that figure.

6 Oct 2009

Allos Therapeutics to raise funds for preclinical research and clinical development of FOLOTYN

Allos Therapeutics, Inc. today announced that it is offering to sell, subject to market and other conditions, 11,000,000 primary shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

Otsuka Pharmaceutical provided access to BioWa's POTELLIGENT Technology platform

BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).

6 Oct 2009

Molecular biologist receives 2009 Nobel Prize in Physiology or Medicine

Molecular biologist Elizabeth H. Blackburn, PhD, 60, of the University of California, San Francisco, today was named to receive the 2009 Nobel Prize in Physiology or Medicine.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009